Stark Holger, Kathmann Markus, Schlicker Eberhard, Schunack Walter, Schlegel Birgit, Sippl Wolfgang
Johann Wolfgang Goethe-Universität, Institut für Pharmazeutische Chemie, Biozentrum, Marie-Curie-Strasse 9, 60439 Frankfurt am Main, Germany.
Mini Rev Med Chem. 2004 Nov;4(9):965-77. doi: 10.2174/1389557043403107.
The first antagonists known for the histamine H3 receptor were mono-substituted imidazole-containing compounds like thioperamide. Meanwhile numerous novel leads have been developed possessing improved affinities, selectivities, specificities, and pharmacokinetic properties. Scope and limitations of this promising class are discussed concerning their structure-activity relationships as well as pharmacological and potential therapeutic aspects.